Atomistry » Bromine » PDB 7yvx-8adf » 7zuq
Atomistry »
  Bromine »
    PDB 7yvx-8adf »
      7zuq »

Bromine in PDB 7zuq: Human PRMT5:MEP50 Crystal Structure with Mta and Fragment Bound

Enzymatic activity of Human PRMT5:MEP50 Crystal Structure with Mta and Fragment Bound

All present enzymatic activity of Human PRMT5:MEP50 Crystal Structure with Mta and Fragment Bound:
2.1.1.320;

Protein crystallography data

The structure of Human PRMT5:MEP50 Crystal Structure with Mta and Fragment Bound, PDB code: 7zuq was solved by M.U.Ahmad, W.Koelmel, V.Arkhipova, J.D.Lawson, C.R.Smith, R.J.Gunn, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å) 109.26 / 2.48
Space group I 2 2 2
Cell size a, b, c (Å), α, β, γ (°) 102.862, 138.228, 178.365, 90, 90, 90
R / Rfree (%) 22.7 / 27.9

Bromine Binding Sites:

The binding sites of Bromine atom in the Human PRMT5:MEP50 Crystal Structure with Mta and Fragment Bound (pdb code 7zuq). This binding sites where shown within 5.0 Angstroms radius around Bromine atom.
In total only one binding site of Bromine was determined in the Human PRMT5:MEP50 Crystal Structure with Mta and Fragment Bound, PDB code: 7zuq:

Bromine binding site 1 out of 1 in 7zuq

Go back to Bromine Binding Sites List in 7zuq
Bromine binding site 1 out of 1 in the Human PRMT5:MEP50 Crystal Structure with Mta and Fragment Bound


Mono view


Stereo pair view

A full contact list of Bromine with other atoms in the Br binding site number 1 of Human PRMT5:MEP50 Crystal Structure with Mta and Fragment Bound within 5.0Å range:
probe atom residue distance (Å) B Occ
A:Br703

b:33.9
occ:1.00
BR1 A:UNL703 0.0 33.9 1.0
C13 A:UNL703 1.9 30.0 1.0
NZ A:LYS333 2.8 44.5 1.0
C12 A:UNL703 2.8 30.4 1.0
C1 A:UNL703 2.9 28.6 1.0
N1 A:UNL703 3.0 27.7 1.0
OE2 A:GLU435 3.1 25.5 1.0
CD2 A:PHE327 3.4 32.8 1.0
CD A:GLU435 3.6 26.5 1.0
O A:GLU435 3.7 29.2 1.0
CB A:GLU435 3.8 27.6 1.0
CG A:PHE327 3.8 33.1 1.0
CE2 A:PHE327 3.9 33.3 1.0
CG A:GLU435 3.9 27.1 1.0
C11 A:UNL703 4.1 29.6 1.0
N2 A:UNL703 4.1 28.1 1.0
S5' A:MTA701 4.2 23.3 1.0
CB A:PHE327 4.2 32.7 1.0
CE A:LYS333 4.2 43.7 1.0
OE1 A:GLU435 4.4 25.5 1.0
CS A:MTA701 4.4 23.3 1.0
OH A:TYR334 4.4 40.0 1.0
CD1 A:PHE327 4.6 33.8 1.0
C2 A:UNL703 4.6 28.8 1.0
CZ A:PHE327 4.6 33.8 1.0
C A:GLU435 4.7 28.3 1.0
CA A:GLU435 4.8 27.6 1.0
CE1 A:PHE327 4.9 33.6 1.0
CZ2 A:TRP579 5.0 30.6 1.0

Reference:

C.R.Smith, S.Kulyk, M.U.D.Ahmad, V.Arkhipova, J.G.Christensen, R.J.Gunn, A.Ivetac, J.M.Ketcham, J.Kuehler, J.D.Lawson, N.C.Thomas, X.Wang, M.A.Marx. Fragment Optimization and Elaboration Strategies - the Discovery of Two Lead Series of PRMT5/Mta Inhibitors From Five Fragment Hits Rsc Med Chem 2022.
ISSN: ESSN 2632-8682
DOI: 10.1039/D2MD00163B
Page generated: Thu Jul 11 04:49:53 2024

Last articles

Zn in 9MJ5
Zn in 9HNW
Zn in 9G0L
Zn in 9FNE
Zn in 9DZN
Zn in 9E0I
Zn in 9D32
Zn in 9DAK
Zn in 8ZXC
Zn in 8ZUF
© Copyright 2008-2020 by atomistry.com
Home   |    Site Map   |    Copyright   |    Contact us   |    Privacy